1,026
Views
4
CrossRef citations to date
0
Altmetric
Editorials: Cell Cycle Features

Adaptive aneuploidy counters a dysregulated SUMO system

&
Pages 383-385 | Received 23 Oct 2016, Accepted 27 Oct 2016, Published online: 17 May 2017

Figures & data

Figure 1. Overproduced Ccr4 or Cln3 suppresses aneuploidy triggered by loss of Ulp2. Loss of Ulp2 (top right) leads to accumulation of polySUMO-conjugated substrates, duplication of Chromosome I (ChrI) and XII, and reduced cell fitness (irregular cell outline). Increased dosage of CCR4 (bottom left) suppresses the aneuploidy and growth defects and partially reduces the aberrantly high SUMO-conjugate levels of ulp2Δ cells (CitationRef.4 and unpublished data). Overexpressing CLN3 (bottom right) suppresses the ChrI, but not ChrXII, disomy, likely through (partial) normalization of cell-cycle progression.

Figure 1. Overproduced Ccr4 or Cln3 suppresses aneuploidy triggered by loss of Ulp2. Loss of Ulp2 (top right) leads to accumulation of polySUMO-conjugated substrates, duplication of Chromosome I (ChrI) and XII, and reduced cell fitness (irregular cell outline). Increased dosage of CCR4 (bottom left) suppresses the aneuploidy and growth defects and partially reduces the aberrantly high SUMO-conjugate levels of ulp2Δ cells (CitationRef.4 and unpublished data). Overexpressing CLN3 (bottom right) suppresses the ChrI, but not ChrXII, disomy, likely through (partial) normalization of cell-cycle progression.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.